Anton Franken, MD, PhD: Monitoring Patients Who Switch to Biosimilars

Video

Anton Franken, MD, PhD, endocrinologist, discusses how closely patients who switch to biosimilars must be monitored.

Transcript:

It depends on the kind of drug. If you look at insulin, it’s a very safe drug. It’s a small drug. It's a very safe drug, but you must follow patients who react. If you look at [tumor necrosis factor, TNF] blockers, infliximab, they have a chance for immunogenicity, so you have to follow them for a long time, but the discussion in the last session was [that] if a biosimilar is approved by [the European Medicines Agency, EMA], it is equally effective and safe, because all the aspects were researched during the registration process. So I think you must follow a patients, but not too intensively.

Related Videos
Chelsee Jensen, PharmD, BCPS
Ryan Haumschild, PharmD, MS, MBA
Stephen Hanauer, MD, professor of medicine, Feinberg School of Medicine, Northwestern University,
Stephen Hanauer, MD, professor of medicine, Feinberg School of Medicine, Northwestern University,
Stephen Hanauer, MD
Fran Gregory, PharmD, MBA
Julie Reed, MS
Julie Reed, executive director of the Biosimilars Forum
 Fran Gregory, PharmD, vice president of emerging therapies, Cardinal Health.
Ryan Haumschild, PharmD, MS, MBA
Related Content
© 2023 MJH Life Sciences

All rights reserved.